Related Experiment Videos

Identification of p53 genetic suppressor elements which confer resistance to cisplatin

W M Gallagher1, M Cairney, B Schott

  • 1CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow, UK.

Oncogene
|January 16, 1997
PubMed

Insights

Loss of p53 protein function leads to cisplatin resistance in ovarian cancer cells. Researchers identified specific TP53 gene fragments that confer this resistance, offering new therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Cisplatin resistance is a major challenge in ovarian cancer treatment.
  • The tumor suppressor protein p53 plays a critical role in cellular responses to DNA damage.

Purpose of the Study:

  • To investigate the role of p53 function loss in cisplatin resistance.
  • To identify specific TP53 gene domains that confer cisplatin resistance.

Main Methods:

  • Used a retroviral library to express random TP53 cDNA fragments in cisplatin-resistant A2780 ovarian cancer cells.
  • Isolated and characterized genetic suppressor elements (GSEs) encoding mutant peptides or antisense RNA.
  • Assessed the effect of GSEs on p53 protein levels, DNA damage-induced cell cycle arrest, apoptosis, and cisplatin resistance.

Main Results:

  • Six GSEs were identified, including dominant-negative mutant peptides and antisense RNA targeting TP53.
  • Both types of GSEs induced cisplatin resistance in A2780 cells.
  • Antisense GSEs reduced intracellular p53 levels, while one sense GSE impaired p53-mediated DNA damage responses.
  • A synthetic peptide mimicking a GSE inhibited p53 DNA binding and conferred cisplatin resistance.

Conclusions:

  • Inactivation of p53 function directly confers cisplatin resistance in human ovarian tumor cells.
  • Identified functional domains within p53 capable of independent interactions.
  • Demonstrated the utility of GSEs for identifying biologically active fragments within a library.

Related Concept Videos